TYRA BIOSCIENCES INC

TYRA stock represents shares of Tyra Biosciences, Inc., a clinical-stage biotechnology company listed on the Nasdaq. The ticker TYRA gives investors exposure to a company focused on developing targeted therapies, which means its value is closely tied to research progress and clinical trial outcomes rather than commercial product sales.

Recent performance for TYRA depends on the latest market session and cannot be summarized with fixed figures here. For the most current price changes, percentage moves, and trading volume, please refer to the live TYRA stock quote and performance chart displayed on this page.

Because TYRA is a clinical-stage biotech company, traditional valuation metrics such as the P/E ratio are often not meaningful. Instead, investors may look at price-to-book, enterprise value, and cash balances relative to research spending, while considering pipeline progress and future commercial potential to judge whether the market price reflects reasonable expectations.

TYRA, like many Nasdaq-listed stocks, may be available for trading in pre-market and after-hours sessions through certain brokers. These extended-hours trades can have lower liquidity and wider spreads, so prices may differ from the regular session. Check with your brokerage for specific availability and any associated risks.

TYRA does not currently pay a dividend. As a clinical-stage biotechnology company, it typically reinvests capital into research and development rather than distributing cash to shareholders. For any future updates on a potential dividend policy, investors should review official company announcements or financial filings.

Investing in TYRA carries risks common to clinical-stage biotech companies, including clinical trial failures, regulatory delays, competition, and the need for additional financing. Because revenue may be limited or nonexistent, the stock can be volatile and sensitive to news about drug development, cash runway, and broader market sentiment toward biotech.